Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Losing Ground On Foreign Manufacturing Inspections, House Panel Says

Executive Summary

Congress is refocusing its interest on an FDA issue that it has looked at periodically for more than a decade: drug import safety and the agency's failure to modernize its foreign inspections program

You may also be interested in...



New Faces Will Lead Office Of Regulatory Affairs As Two Top Officials Depart

The face of FDA's Office of Regulatory Affairs will undergo a major change as two senior leaders leave the office responsible for managing inspections and enforcement activity

New Faces Will Lead Office Of Regulatory Affairs As Two Top Officials Depart

The face of FDA's Office of Regulatory Affairs will undergo a major change as two senior leaders leave the office responsible for managing inspections and enforcement activity

Editor’s Perspective: Is The Ketek Scandal Good For Big Pharma? Generic Biologic Bill Could Suffer

It was not a pretty sight in Room 2123 of the Rayburn House Office Building on Feb. 12, where the House's Energy and Commerce Committee's Oversight and Investigations Subcommittee held a hearing on fraud in the studies of the antibiotic Ketek. The head of Sanofi-Aventis' U.S. R&D had to acknowledge he could not verify that other studies were free from fraud, and committee members lambasted FDA Commissioner Andrew von Eschenbach in absentia

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel